PB 42 of 2022
National Health (Pharmaceutical Benefits)
(Pharmacist Substitution of Medicines without
Prescription during Shortages) Amendment (No. 2) Determination 2022
I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 18 May 2022
Nikolai Tsyganov
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
1 Name ........................................................................................................................... 1
2 Commencement .......................................................................................................... 1
3 Authority ..................................................................................................................... 1
4 Schedules .................................................................................................................... 1
Schedule 1—Amendments National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines | 2 |
without Prescription during Shortages) Determination 2021 | 2 |
(1) This instrument is the National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Amendment (No. 2) Determination 2022.
(2) This instrument may also be cited as PB 42 of 2022.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
| |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 20 May 2022. | 20 May 2022. |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument.
Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 89A(3) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1 Amendments
National Health (Pharmaceutical Benefits) (Pharmacist Substitution of
Medicines without Prescription during Shortages) Determination 2021
1 Subsection 5(8), omit:
Listed drug: Tocilizumab | Listed drug: Tocilizumab | |
| Form: Injection 162 mg in 0.9 mL single use pre‑filled syringe | Form: Injection 162 mg in 0.9 mL single use pre‑filled pen |
| Manner of administration: Injection | Manner of administration: Injection |
| Brand: Actemra Subcutaneous Injection | Brand: Actemra ACTPen |
2 | Listed drug: Tocilizumab | Listed drug: Tocilizumab |
| Form: Injection 162 mg in 0.9 mL single use pre‑filled pen | Form: Injection 162 mg in 0.9 mL single use pre‑filled syringe |
| Manner of administration: Injection | Manner of administration: Injection |
| Brand: Actemra ACTPen | Brand: Actemra Subcutaneous Injection |
3 | Listed drug: Estradiol | Listed drug: Estradiol |
| Form: Tablet containing estradiol valerate 1 mg | Form: Tablet 2 mg |
| Manner of administration: Oral | Manner of administration: Oral |
| Brand: Progynova | Brand: Zumenon |
4 | Listed drug: Estradiol | Listed drug: Estradiol |
| Form: Tablet containing estradiol valerate 2 mg | Form: Tablet 2 mg |
| Manner of administration: Oral | Manner of administration: Oral |
| Brand: Progynova | Brand: Zumenon |